MedPath

Epidemiology of High-risk HPV Infection in Women Participating in a Pilot Screening Program for Cervical Cancer

Completed
Conditions
HPV Infection
Interventions
Biological: Human papillomavirus genotyping
Registration Number
NCT02809352
Lead Sponsor
CHU de Reims
Brief Summary

Cervical cancer is due to a persistent infection with a group of viruses known as high-risk Human Papillomaviruses (hrHPV). Viral DNA can be easily detected in a cervical sample by a procedure called 'HPV testing', which can be used as a relevant screening test. A pilot screening program called START-HPV has been set up in the Ardennes, a French administrative area localized in the North of France, with HPV testing as a primary screening test.This observational study aimed to evaluate hrHPV genotypes repartition in the population who participate in the START-HPV screening program. This study will allow a better knowledge of hrHPV infection epidemiology in a screened population.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
348
Inclusion Criteria
  • to live in the Ardennes department (France)
  • affiliation to a health insurance organism
  • 31 to 65 years old
Exclusion Criteria
  • current follow-up for cervical cytological abnormalities
  • history of hysterectomy
  • reimbursement for a Pap smear in the last 3 years

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
women tested positive for hrHPVHuman papillomavirus genotypingAll women participating in START-HPV pilot program for cervical cancer screening and tested positive for hrHPV with the Hybrid Capture 2 test (Qiagen).
Primary Outcome Measures
NameTimeMethod
HPV genotypingDay 0

DNA extraction from cervical smears (DNAPap Cervical Sampler device, Qiagen) or from self-collected vaginal lavages (Delphi-screener device, DelphiBioscience) and HPV genotyping with the Multiplex HPV Genotyping kit© (Multimetrix, Progen) based on a Luminex technology

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chu Reims

🇫🇷

France, Reims, France

© Copyright 2025. All Rights Reserved by MedPath